ABCB1 p.Leu975Ala

[switch to full view]
Comments [show]
Publications
PMID: 10331089 [PubMed] Ambudkar SV et al: "Biochemical, cellular, and pharmacological aspects of the multidrug transporter."
No. Sentence Comment
47 Table 1 List of mutations in human, mouse, and hamster P-glycoproteins that affect substrate specificitya aa mutation Region Sourceb Reference H61R, F, K, M, W, Y TM 1 Human MDR1 149, 150 ABC20c G64R TM 1 Human MDR1 150 L65R TM 1 Human MDR1 150 aa78-97 EC 1 Human MDR1 151 Q128Hd TM 2 Mouse mdr3 152 R138H IC 1 Mouse mdr3 152 Q139H, R IC 1 Mouse mdr3 152 Q141V IC 1 Human MDR1 15319, Q145H IC 1 Mouse mdr3 152 E155G, K IC 1 Mouse mdr3 152 F159I IC 1 Mouse mdr3 152 D174G IC 1 Mouse mdr3 152 S176G, P IC 1 Mouse mdr3 152 K177I IC 1 Mouse mdr3 152 N179S IC 1 Mouse mdr3 152 N183S/G185V IC 1 Human MDR1 154 G183D IC 1 Mouse mdr3 152 G185V IC 1 Human MDR1 155-157 G187V IC 1 Human MDR1 153 A192T TM 3 Mouse mdr3 152 F204S EC 2 Mouse mdr3 152 W208G EC 2 Mouse mdr3 152 K209E EC 2 Mouse mdr3 152 L210I TM 4 Mouse mdr3 152 T211P TM 4 Mouse mdr3 152 I214T TM 4 Mouse mdr3 152 P223A TM 4 Human MDR1 158 G288V IC 2 Human MDR1 153 I299M, T319S, L322I, TM 5, EC3, Human MDR1 159 G324K, S351N IC 3 F335A TM 6 Human MDR1 19 F335 TM 6 Human MDR1 160 V338A TM 6 Human MDR1 161 G338A, A339P TM 6 Hamster PGY1 162, 163 A339P TM 6 Hamster PGY1 163 G341V TM 6 Human MDR1 161 K536R, Q N-NBD Human MDR1 164 ERGA → DKGT N-NBD Mouse mdr3 165 aa 522-525 T578C N-NBD Mouse mdr3 165 (Continued) G830V IC 4 Human MDR1 P866A TM 10 Human MDR1 158 F934A TM 11 Mouse mdr3 166 G935A TM 11 Mouse mdr3 166 I936A TM 11 Mouse mdr3 166 F938A TM 11 Mouse mdr3 166 S939A TM 11 Mouse mdr3 166 S939F TM 11 Mouse mdr3 167, 168 S941F TM 11 Mouse mdr1 167, 168 T941A TM 11 Mouse mdr3 166 Q942A TM 11 Mouse mdr3 166 A943G TM 11 Mouse mdr3 166 Y946A TM 11 Mouse mdr3 166 S948A TM 11 Mouse mdr3 166 Y949A TM 11 Mouse mdr3 166 C952A TM 11 Mouse mdr3 166 F953A TM 11 Mouse mdr3 166 F983A TM 12 Human MDR1 169 L975A, V981A, F983A TM 12 Human MDR1 169 M986A, V988A, Q990A, TM 12 Human MDR1 169 V991A V981A, F983A TM 12 Human MDR1 169 L975A, F983A TM 12 Human MDR1 169 L975A, V981A TM 12 Human MDR1 169 F978A TM 12 Human MDR1 19 a aa,amino acid; EC, extracellular loop; IC, intracellular loop; TM,transmembrane domain; NBD, nucleotide binding/utilization domain.
X
ABCB1 p.Leu975Ala 10331089:47:1768
status: NEW
X
ABCB1 p.Leu975Ala 10331089:47:1891
status: NEW
X
ABCB1 p.Leu975Ala 10331089:47:1925
status: NEW
Login to comment

PMID: 10350482 [PubMed] Dey S et al: "A single amino acid residue contributes to distinct mechanisms of inhibition of the human multidrug transporter by stereoisomers of the dopamine receptor antagonist flupentixol."
No. Sentence Comment
127 In a recent study, seven amino acid residues, L975, V981, F983, M986, V988, Q990, and V991, in the putative TM 12 of human Pgp were substituted individually by alanine (L975A, V981A, F983A, M986A, V988A, Q990A, and V991A).
X
ABCB1 p.Leu975Ala 10350482:127:169
status: NEW
Login to comment

133 Consistent with the previous report, all the mutant Pgp`s (L975A, V981A, F983A, M986A, V988A, Q990A, and V991A) were expressed on the cell surface at a comparable level to that of wild-type (WT) Pgp (Figure 1A, upper panel).
X
ABCB1 p.Leu975Ala 10350482:133:59
status: NEW
Login to comment

141 Human osteosarcoma (HOS) cells infected with vTF7-3 were transfected with either pTM1 (control) (s), pTM1-MDR1 (wild type) (-), pTM1-MDR1-L975A (L975A) (‚‚‚), pTM1-MDR1-V981A (V981A) (- - -), pTM1-MDR1-F983A (F983A) (- -), pTM1-MDR1-M986A (M986A) (thick dashes), pTM1-MDR1-V988A (V988A) (-‚‚-), pTM1-MDR1-Q990A (Q990A) (-‚-), or pTM1-MDR1-V991A (V991A) (-‚‚‚-) plasmid DNA.
X
ABCB1 p.Leu975Ala 10350482:141:138
status: NEW
X
ABCB1 p.Leu975Ala 10350482:141:145
status: NEW
Login to comment

143 (A, upper panel) Cells were subjected to FACS analysis after staining with human Pgp external epitope-specific monoclonal antibody MRK-16 (14), as described under Experimental Procedures. (A, lower panel) Total cell lysates were prepared from each cell type, and immunoblot analysis with Pgp-specific monoclonal antibody C219 was performed as described under Experimental Procedures. (B) Similar to section A; cells were infected with vTF7-3, and transfected with either pTM1 (control) (s), pTM1-MDR1 (wild type) (-), pTM1-MDR1-L975A (L975A) (‚‚‚), pTM1-MDR1-V981A (V981A) (- - -), pTM1-MDR1-F983A (F983A) (- -), pTM1-MDR1-M986A (M986A) (thick dashes) pTM1-MDR1-V988A (V988A) (-‚‚-), pTM1-MDR1-Q990A (Q990A) (-‚-), or pTM1-MDR1-V991A (V991A) (-‚‚‚-) plasmid DNAs.
X
ABCB1 p.Leu975Ala 10350482:143:528
status: NEW
X
ABCB1 p.Leu975Ala 10350482:143:535
status: NEW
Login to comment

155 In the presence of 10 µM cis(Z)-flupentixol or 5 µM trans(E)-flupentixol, the intracellular accumulation of Bodipy FL-verapamil in HOS cells expressing either wild-type Pgp or L975A was increased to approximately the same level as that of the control cells (Figure 2A,B), which had no detectable expression of Pgp, suggesting effective inhibition of Pgp-mediated efflux from the cells.
X
ABCB1 p.Leu975Ala 10350482:155:186
status: NEW
Login to comment

156 The effects of both cis(Z)- and trans(E)-flupentixol on accumulation of Bodipy FL-verapamil in cells expressing V988A, Q990A, or V991A were identical to that observed in L975A (data not shown), suggesting that none of these substitutions affects inhibition of transport by flupentixol.
X
ABCB1 p.Leu975Ala 10350482:156:170
status: NEW
Login to comment

165 Steady-state accumulation of Bodipy FL-verapamil was measured by FACS in the presence (- - -) and absence (s) of 10 µM cis(Z)-flupentixol (A) or 5 µM trans(E)-flupentixol (B) in HOS cells infected with vTF7-3 and transfected with either pTM1 (pTM1), pTM1-MDR1 (WT), pTM1-MDR1-L975A (L975A), pTM1-MDR1-V981A (V981A), or pTM1-MDR1-F983A (F983A).
X
ABCB1 p.Leu975Ala 10350482:165:286
status: NEW
X
ABCB1 p.Leu975Ala 10350482:165:293
status: NEW
Login to comment

PMID: 9819232 [PubMed] Hafkemeyer P et al: "Contribution to substrate specificity and transport of nonconserved residues in transmembrane domain 12 of human P-glycoprotein."
No. Sentence Comment
7 Substitutions including L975A in combination with any one of the other two replacements had the least effect on Pgp function.
X
ABCB1 p.Leu975Ala 9819232:7:24
status: NEW
Login to comment

50 Moreover, double mutants based on the triple mutant were cloned (L975A-V981A-F983, L975A-V981-F983A, L975- V981A-F983A).
X
ABCB1 p.Leu975Ala 9819232:50:65
status: NEW
X
ABCB1 p.Leu975Ala 9819232:50:83
status: NEW
Login to comment

98 Alanine mutants were arranged in such a way that three alanine mutations were putatively located in the outer plasma membrane leaflet (L975A, V981A, and F983A) and four in the inner leaflet (M986A, V988A, Q990A, and V991A), assuming an R-helical structure to TM 12 (Figure 1b).
X
ABCB1 p.Leu975Ala 9819232:98:135
status: NEW
Login to comment

124 Double mutants combining pairwise L975A, V981A, and F983A were constructed in order to determine the critical nonconserved residues that were responsible for mediating drug transport in the amino-proximal half of TM 12.
X
ABCB1 p.Leu975Ala 9819232:124:34
status: NEW
Login to comment

125 Those double mutants were L975A-V981A, L975A-F983A, and V981A-F983A.
X
ABCB1 p.Leu975Ala 9819232:125:26
status: NEW
X
ABCB1 p.Leu975Ala 9819232:125:39
status: NEW
Login to comment

126 The V981-F983 double mutant was Table 1: Properties of Wild-Type and Mutant P-glycoproteinsa drug transporta cell surface expressionc rhodamine daunomycin bodipy-verapamil calcein-AM bodipy-taxol wild-type ++++ ++++ ++++ ++++ ++++ ++++ L975A ++++ ++++ ++++ ++++ ++++ ++++ V981A ++++ ++++ ++++ ++++ ++++ ++++ F983A ++++ ++++ ++++ ++++ ++++ ++++ M986A ++++ ++++ n.d. ++++ ++++ n.d. V988A ++++ ++++ n.d. ++++ ++++ n.d. Q990A ++++ ++++ n.d. ++++ ++++ n.d. V991A ++++ ++++ n.d. ++++ ++++ n.d. L975A, V981A, F983A ++++ no transport no transport ++ ++ ++ M986A, V988A, Q990A, V991A ++++ ++++ +++ ++ ++++ ++++ V981A, F983A ++++ + no transport ++ ++ +++ L975A, F983A ++++ + ++ ++++ +++ ++++ L975A, V981A ++++ ++ no transport ++++ +++ ++++ a Symbols are noted as follows: ++++, wild-type activity; ++, impaired activity; +, residual activity; and n.d., not determined. b Drug transport was determined by FACS.
X
ABCB1 p.Leu975Ala 9819232:126:236
status: NEW
X
ABCB1 p.Leu975Ala 9819232:126:488
status: NEW
X
ABCB1 p.Leu975Ala 9819232:126:645
status: NEW
X
ABCB1 p.Leu975Ala 9819232:126:682
status: NEW
Login to comment

130 Mutant Pgp`s are the triple mutant in the amino-proximal half of TM 12 (L975A-V981A-F983A, - -), the quadruple mutant in the carboxy-terminal half of TM 12 (M986A-V988A-Q990A-V991A, ‚‚‚), the double mutants L975A-V981A (- - -), L975A-F983A (-‚‚-), and V981A-F983A (-‚-).
X
ABCB1 p.Leu975Ala 9819232:130:72
status: NEW
X
ABCB1 p.Leu975Ala 9819232:130:228
status: NEW
X
ABCB1 p.Leu975Ala 9819232:130:249
status: NEW
Login to comment

134 The double mutants involving L975A and either V981A and/or F983A were still capable of transporting calcein-AM, bodipy-taxol, and bodipy-verapamil but rhodamine 123 and daunorubicin transport was significantly reduced compared to wild-type Pgp (Figure 4), indicating a significant contribution of L975 to drug specificity.
X
ABCB1 p.Leu975Ala 9819232:134:29
status: NEW
Login to comment

141 Mutant Pgp`s are the triple mutant in the amino-proximal half of TM 12 (L975A-V981A-F983A) and the quadruple mutant (M986A-V988A-Q990A-V991A) (s).
X
ABCB1 p.Leu975Ala 9819232:141:72
status: NEW
Login to comment

144 Photoaffinity labeling demonstrated that the triple mutant L975A-V981A-F983A displayed a significant reduction in binding of IAAP compared to wild-type Pgp which is consistent with its reduced drug transport ability (Figure 5b).
X
ABCB1 p.Leu975Ala 9819232:144:59
status: NEW
Login to comment

147 The three double mutants L975A-V981A, L975A-F983A, and V981A-F983A were able to bind IAAP but somewhat less than wild-type Pgp as was also true for the single mutants investigated in this study (Figure 5b,c).
X
ABCB1 p.Leu975Ala 9819232:147:25
status: NEW
X
ABCB1 p.Leu975Ala 9819232:147:38
status: NEW
Login to comment

153 Mutant MDR1s are double mutants L975A-V981A, L975A-F983A, and V981A-F983A (s).
X
ABCB1 p.Leu975Ala 9819232:153:32
status: NEW
X
ABCB1 p.Leu975Ala 9819232:153:45
status: NEW
Login to comment

156 The double and single mutants displayed near wild-type levels of verapamil-stimulated ATPase activity except for L975A-V981A (Figure 6b).
X
ABCB1 p.Leu975Ala 9819232:156:113
status: NEW
Login to comment

159 ATP binding was equivalent for wild-type MDR1 and the MDR1 mutants L975A-V981A-F983A as well as for M986A-V988A-Q990A-V991A (Figure 7).
X
ABCB1 p.Leu975Ala 9819232:159:67
status: NEW
Login to comment

162 Vanadate-trapped [R-32P]-8-azido-ADP was significantly reduced in the triple mutant L975A-V981A-F983A (Figure 8b,c), consistent with the decrease a b c FIGURE 5: Photoaffinity labeling of wild-type and mutant Pgp`s.
X
ABCB1 p.Leu975Ala 9819232:162:84
status: NEW
Login to comment

174 (a) pTM: cells infected with vTF 7-3 virus and transfected with the expression vector containing no MDR1 (pTM1) (negative control), WT (wild-type human MDR1), and mutant Pgp`s are the triple mutant in the amino-proximal half of TM 12 (L975A-V981A-F983A) and the quadruple mutant in the carboxy-terminal half of TM 12 (M986A- V988A-Q990A-V991A).
X
ABCB1 p.Leu975Ala 9819232:174:235
status: NEW
Login to comment

176 Mutant MDR1s are the three double mutants L975A-V981A, L975A-F983A, and V981A-F983A.
X
ABCB1 p.Leu975Ala 9819232:176:42
status: NEW
X
ABCB1 p.Leu975Ala 9819232:176:55
status: NEW
Login to comment

188 pTM: cells infected with vTF 7-3 virus and transfected with the expression vector containing no MDR1 (pTM1) (negative control), WT (wild-type human MDR1), the triple mutant in the amino-proximal half of TM 12 (L975A-V981A-F983A), the quadruple mutant in the carboxy-terminal half of TM 12 (M986A- V988A-Q990A-V991A), WT (wild-type human MDR1) in the presence of 250 µM EDTA and without MgCl2 to assess the specificity of the 170 kDa band representing Pgp as indicated with the arrow.
X
ABCB1 p.Leu975Ala 9819232:188:210
status: NEW
Login to comment

193 (Middle panel) Vanadate-induced [R-32P]-8-azido-ADP labeling was performed at 37 °C. pTM: cells infected with vTF 7-3 virus and transfected with the expression vector containing no MDR1 (pTM1) (negative control), WT (wild-type human MDR1), the triple mutant in the amino-proximal half of TM 12 (L975A-V981A-F983A), and the quadruple mutant in the carboxy-terminal half of TM 12 (M986A- V988A-Q990A-V991A).
X
ABCB1 p.Leu975Ala 9819232:193:300
status: NEW
Login to comment

227 To determine which combinations of these three residues of TM 12 predicted to lie in the outer leaflet were responsible for the loss of transport activity, we constructed double mutants (L975A-V981A, L975A-F983A, and V981A-F983A).
X
ABCB1 p.Leu975Ala 9819232:227:187
status: NEW
X
ABCB1 p.Leu975Ala 9819232:227:200
status: NEW
Login to comment

228 The double mutants showed reduced drug transport suggesting that a change in any two of these three amino Table 2: Properties of Wild-Type and Mutant P-Glycoproteinsa photoaffinity labelinga ATP bindingb ATPase activityc wild-type ++++ ++++ ++++ L975A +++ n.d. +++ V981A +++ n.d. +++ F983A +++ n.d. +++ M986A n.d. n.d. n.d. V988A n.d. n.d. n.d. Q990A n.d. n.d. n.d. V991A n.d. n.d. n.d. L975A,V981A, F983A + ++++ + M986A, V988A, Q990A, V991A ++ ++++ ++ V981A, F983A +++ n.d. +++ L975A, F983A +++ n.d. +++ L975A, V981A +++ n.d. +++ a Symbols are noted as follows: ++++, wild-type activity; ++, impaired activity; +, residual activity; and n.d. not determined. b Photoaffinity labeling was done in HeLa crude membrane preparations using [125 I]iodoarylazidoprazosin.
X
ABCB1 p.Leu975Ala 9819232:228:246
status: NEW
X
ABCB1 p.Leu975Ala 9819232:228:387
status: NEW
X
ABCB1 p.Leu975Ala 9819232:228:479
status: NEW
X
ABCB1 p.Leu975Ala 9819232:228:505
status: NEW
Login to comment

PMID: 16545467 [PubMed] Shilling RA et al: "New light on multidrug binding by an ATP-binding-cassette transporter."
No. Sentence Comment
58 Although mutation of only one of these residues (L975A, V981A and F983A) has no effect on the phenotype of the protein [20], double mutations either completely inhibit (V981A/F983A and L975A/V981A) or cause 50% inhibition (L975A/F983A) of Table 1.
X
ABCB1 p.Leu975Ala 16545467:58:49
status: NEW
X
ABCB1 p.Leu975Ala 16545467:58:185
status: NEW
X
ABCB1 p.Leu975Ala 16545467:58:223
status: NEW
X
ABCB1 p.Leu975Ala 16545467:58:641
status: NEW
Login to comment

59 Published mutations in human and murine P-glycoprotein that alter drug transport in cells Location of mutation Mutation Refs Mutation Refs Mutation Refs Transmembrane helices H61A and others [14] I214L [60] L868W [59] G64R [15] P223A [65] I936A [21] L65R [15] S224P [60] F938A [21] Q139[H/P/R] [60] I306R [18] S939[A/C/T/Y/W/D/F] [21,22] G141V [17] F335A [16] T941A [21] G185V [61,62] V338A [66] Q942A [21] I186N [61] G338A [67,68] A943G [21] G187V [17] A339P [67,68] Y946A [21] G187E [60] G341A [66] S948A [21] A192T [60] S344[A/T/C/Y] [66] Y949A [21] F200L [60] N350I [19] C952A [21] F204S [60] P709A [65] F953A [21] R206L [60] G830V [17] L975A [20] W208G [60] I837L [23] F978A [16] K209E [60] N839I [23] V981A [20] L210I [60] I862F [19] F983A [20] T211P [60] L865F [19] F978A [16] V213A [60] P866A [65] N988D [59] Intracellular domain T169I [60] K177I [60] G288V [17] R170L [60] E180G [60] A931T [19] L171P [60] G181R [60] F934A [21] T172P [60] G183D [60] G935A [21] S176P [60] D184N [60] NBD D555N [63] K1076M [69] E1197Q [64] D558N [64] D1093N [64] D1203N [64] D592N [64] E1125Q [64] D1237N [64] E604Q [64] S1173A [70] E1249Q [64] Review TRENDS in Pharmacological Sciences Vol.27 No.
X
ABCB1 p.Leu975Ala 16545467:59:42
status: NEW
X
ABCB1 p.Leu975Ala 16545467:59:58
status: NEW
X
ABCB1 p.Leu975Ala 16545467:59:641
status: NEW
Login to comment

61 The same mutations have either no effect (L975A/F983A and L975A/V981A) or cause up to 50% inhibition (V981A/ F983A) in the transport of bodipy-verapamil, calcein-AM and bodipy-taxol.
X
ABCB1 p.Leu975Ala 16545467:61:42
status: NEW
X
ABCB1 p.Leu975Ala 16545467:61:58
status: NEW
Login to comment

57 Although mutation of only one of these residues (L975A, V981A and F983A) has no effect on the phenotype of the protein [20], double mutations either completely inhibit (V981A/F983A and L975A/V981A) or cause 50% inhibition (L975A/F983A) of Table 1.
X
ABCB1 p.Leu975Ala 16545467:57:49
status: NEW
X
ABCB1 p.Leu975Ala 16545467:57:185
status: NEW
X
ABCB1 p.Leu975Ala 16545467:57:223
status: NEW
Login to comment

PMID: 11428917 [PubMed] Hrycyna CA et al: "Molecular genetic analysis and biochemical characterization of mammalian P-glycoproteins involved in multidrug resistance."
No. Sentence Comment
27 List of mutations in human, mouse and hamster P-gp`s that affect substrate specificity f aaa Mutation Regionb Sourcec Reference aa 78-97 EC 1 human MDR1 78 (ABC20)d Q128He TM 2 mouse mdr3 79 R138H IC 1 mouse mdr3 79 Q139H, R IC 1 mouse mdr3 79 G141V IC 1 human MDR1 25,80 Q145H IC 1 mouse mdr3 79 E155G, K IC 1 mouse mdr3 79 F159I IC 1 mouse mdr3 79 D174G IC 1 mouse mdr3 79 S176F, P IC 1 mouse mdr3 79 K177I IC 1 mouse mdr3 79 N179S IC1 mouse mdr3 79 N183S/G185V IC 1 human MDR1 81 G183D IC1 mouse mdr3 79 G185V IC 1 human MDR1 82-84 G187V IC 1 human MDR1 80 A192T TM 3 mouse mdr3 79 F204S EC 2 mouse mdr3 79 W208G EC 2 mouse mdr3 79 K209E EC 2 mouse mdr3 79 L210I TM 4 mouse mdr3 79 T211P TM 4 mouse mdr3 79 I214T TM 4 mouse mdr3 79 P223A TM 4 human MDR1 85 K285T IC 2 human MDR1 1 G288V IC 2 human MDR1 80 I299M, T319S, L322I, TM 5, EC3, IC 3 human MDR1 86 G324K, S351N V334 TM 6 human MDR1 1 F335A TM 6 human MDR1 25 F335 TM 6 human MDR1 87 V338A TM 6 human MDR1 88 G338A, A339P TM 6 hamster PGY 1 89,90 A339P TM 6 hamster PGY 1 90 G341V TM 6 human MDR1 88 K536R,Q N-NBD human MDR1 91 ERGA→DKGT N-NBD mouse mdr3 92 (aa 522-525) T578C N-NBD mouse mdr3 92 G812V IC 4 human MDR1 80 G830V IC 4 human MDR1 25,80 P866A TM 10 human MDR1 85 F934A TM 11 mouse mdr3 93 G935A TM 11 mouse mdr3 93 I936A TM 11 mouse mdr3 93 F938A TM 11 mouse mdr3 93 S939A TM 11 mouse mdr3 93 S939F TM 11 mouse mdr3 94,95 S941F TM 11 mouse mdr1 94,95 T941A TM 11 mouse mdr3 93 Q942A TM 11 mouse mdr3 93 Table 1-continued aaa Mutation Regionb Sourcec Reference A943G TM 11 mouse mdr3 93 Y946A TM 11 mouse mdr3 93 S948A TM 11 mouse mdr3 93 Y949A TM 11 mouse mdr3 93 C952A TM 11 mouse mdr3 93 F953A TM 11 mouse mdr3 93 F983A TM 12 human MDR1 96 L975A, V981A, F983A TM 12 human MDR1 96 M986A, V988A, TM 12 human MDR1 96 Q990A, V991A V981A, F983A TM 12 human MDR1 96 L975A, F983A TM 12 human MDR1 96 L975A, V981A TM 12 human MDR1 96 F978 TM 12 human MDR1 1 F978A TM 12 human MDR1 25 a aa, amino acid.
X
ABCB1 p.Leu975Ala 11428917:27:1726
status: NEW
X
ABCB1 p.Leu975Ala 11428917:27:1731
status: NEW
X
ABCB1 p.Leu975Ala 11428917:27:1846
status: NEW
Login to comment

PMID: 23104431 [PubMed] Gozalpour E et al: "Interaction of digitalis-like compounds with p-glycoprotein."
No. Sentence Comment
10 The uptake of [3 H]-N-methyl-quinidine (NMQ), the P-gp substrate in vesicular transport assays, was determined.The mutations I306A, F343A, F728A,T945A, and L975A abolished NMQ transport activity of P-gp.
X
ABCB1 p.Leu975Ala 23104431:10:156
status: NEW
Login to comment

45 Removal of the side chain resulted in loss of NMQ transport activity of five human P-gp mutants: I306A, F343A, F728A, T945A, and L975A, which seem to have key role in the transport of NMQ.
X
ABCB1 p.Leu975Ala 23104431:45:129
status: NEW
Login to comment

62 Ten different P-gp mutants were produced: L65A, I306A, F336A, I340A, F343A, F728A, F942A, T945A, L975A, and V982A and all mutations were confirmed by sequencing of full-length P-gp cDNA.
X
ABCB1 p.Leu975Ala 23104431:62:97
status: NEW
Login to comment

122 All the indicated amino acids were replaced by alanine to remove the side chain of the residue (L65A, I306A, F336A, I340A, F343A, F728A, F942A, T945A, L975A, and V982A).
X
ABCB1 p.Leu975Ala 23104431:122:151
status: NEW
Login to comment

132 NMQ transport activity of mutants L65A, F336A, I340A, F942A, andV982A as compared with wild-type P-gp ranged from 60 to 150%, whereas NMQ transport activity of I306A, F343A, F728A, T945A, and L975A varied between 8 and 30%.
X
ABCB1 p.Leu975Ala 23104431:132:192
status: NEW
Login to comment

180 Fig. 5.ߓ Western blot analysis (A) and NMQ transport activity of wild type and L65A, I306A, F336A, I340A, F343A, F728A, F942A, T945A, L975A, and V982A mutant P-gp (B).
X
ABCB1 p.Leu975Ala 23104431:180:140
status: NEW
Login to comment

190 The first group of mutants (I306A, F343A, F728A, T945A, and L975A) exhibited a significantly lower NMQ transport activity (8-30% of wild-type P-gp).
X
ABCB1 p.Leu975Ala 23104431:190:60
status: NEW
Login to comment

PMID: 25264938 [PubMed] Gozalpour E et al: "Convallatoxin: a new P-glycoprotein substrate."
No. Sentence Comment
56 Nine different P-gp mutants, I306A, F336A, I340A, F343A, F728A, F942A, T945A, L975A, and V982A, were produced and sequencing of full-length P-gp cDNA was used to confirm all mutations (Gozalpour et al., 2013).
X
ABCB1 p.Leu975Ala 25264938:56:78
status: NEW
Login to comment

154 Nine amino acids were replaced by alanine (I306A, F336A, I340A, F343A, F728A, F942A, T945A, L975A, and V982A) and P-gp mutants were expressed in HEK293 cells to produce membrane vesicles.
X
ABCB1 p.Leu975Ala 25264938:154:92
status: NEW
Login to comment

168 The transport activity of F336A, F942A, T945A and L975A for NMQ ranged from 49% to 57%, whereas I340A showed increased activity of 120% and V982A had about the same activity as wild type (Fig. 5B).
X
ABCB1 p.Leu975Ala 25264938:168:50
status: NEW
Login to comment

170 Convallatoxin and NMQ transport activity were not significantly different for I306A, F336A, I340A, F728A, F942A, T945A, and L975A (Fig. 5C), whereas they differed significantly for F343A and V982A (Fig. 5D and E).
X
ABCB1 p.Leu975Ala 25264938:170:124
status: NEW
Login to comment

254 The transport activity of F336A, F942A, T945A, L975A and V982A, were conserved (45-100% of wild type) (Fig. 5B) similar to our previous results (Gozalpour et al., 2013).
X
ABCB1 p.Leu975Ala 25264938:254:47
status: NEW
Login to comment